* AVITA Medical Inc is expected to show a rise in quarterly revenue when it reports results on August 8 for the period ending June 30 2024
* The Valencia California California-based company is expected to report a 23.5% increase in revenue to $14.517 million from $11.75 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
* LSEG's mean analyst estimate for AVITA Medical Inc is for a loss of 54 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for AVITA Medical Inc is A$4.10, above its last closing price of A$2.54.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.49 -0.47 -0.15 Beat 68.9
Dec. 31 0001 -0.41 -0.38 -0.06 Beat 85.3
Sep. 30 2023 -0.44 -0.41 -0.07 Beat 83.5
Jun. 30 2023 -0.34 -0.34 -0.08 Beat 75.8
Mar. -0.32 -0.33 -0.07 Beat 77.3
31 2023
Dec. 31 2022 -0.34
Sep. 30 2022 -0.30
Jun. 30 2022 -0.32
This summary was machine generated August 7 at 03:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments